Aligos Therapeutics Q3 EPS $(0.41) Beats $(0.47) Estimate, Sales $2.15M Miss $2.50M Estimate
Portfolio Pulse from mahesh@benzinga.com
Aligos Therapeutics reported Q3 losses of $(0.41) per share, beating the analyst consensus estimate of $(0.47) by 12.77%. However, the company's quarterly sales of $2.15 million missed the analyst consensus estimate of $2.50 million by 13.84%. This represents a 47.54% decrease in sales compared to the same period last year.
November 02, 2023 | 8:43 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Aligos Therapeutics reported better than expected Q3 EPS but missed on sales. This mixed report could lead to uncertainty in the market.
Aligos Therapeutics reported a better than expected EPS, which is a positive signal for investors. However, the company missed on sales, which is a negative signal. These mixed results could lead to uncertainty in the market, potentially impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100